Overview

GLP-2 (T) is a catalog shorthand commonly used for tirzepatide, a peptide that acts as a dual agonist at the GIP and GLP-1 receptors.
In research, tirzepatide is used to study incretin receptor pharmacology and downstream signaling in controlled experimental systems.

Naming clarification: in physiology, “GLP-2” also refers to a different endogenous gut peptide.
The “GLP-2 (T)” label here indicates the tirzepatide shorthand used by some catalogs.

Key identifiers

• Name: Tirzepatide
• FDA substance registry (UNII): GINAS: OYN3CCI6QE
• CAS (commonly listed): 2023788-19-2
• Registry link: PubChem: Tirzepatide

Mechanistic context (research framing)

Tirzepatide is described in FDA materials as a 39–amino-acid peptide agonist of both GIPR and GLP-1R.
In cell models, these receptors are often studied via canonical GPCR outputs such as cAMP signaling and pathway-biased readouts (assay-dependent).

Research applications

• Receptor profiling: potency/efficacy at GIPR and GLP-1R, kinetics, pathway bias
• Signal transduction assays: second-messenger and transcriptional endpoints in engineered or native cell systems
• Comparative benchmarking: vs GLP-1–only agonists (e.g., semaglutide) in standardized assay panels

Human-use context (background only)

Tirzepatide is the active ingredient in FDA-approved medicines (e.g., Mounjaro for type 2 diabetes; Zepbound for chronic weight management).
This is provided for scientific context only and does not imply intended human use of RUO material.

• FDA label: Mounjaro (tirzepatide)
• FDA label: Zepbound (tirzepatide)

Form, documentation & storage

• Form: often supplied as lyophilized powder for research workflows (confirm on COA)
• Documentation: use the lot COA for purity/identity and handling constraints
• General storage: sealed, dry, protected from light; follow SOPs and COA guidance

RUO disclaimer

For Research Use Only. Not for human or veterinary use. Not for diagnostic or therapeutic purposes.